• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    3/28/24 8:06:10 AM ET
    $AKAN
    $AKBA
    $AVTX
    $IMRN
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Avalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million.
    • Xilio Therapeutics (NASDAQ:XLO) stock moved upwards by 223.94% to $2.07. The market value of their outstanding shares is at $56.9 million.
    • Akanda (NASDAQ:AKAN) shares increased by 27.1% to $0.21. The company's market cap stands at $1.8 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares rose 23.01% to $0.11. The market value of their outstanding shares is at $4.2 million.
    • Akebia Therapeutics (NASDAQ:AKBA) stock increased by 18.34% to $2.65. The company's market cap stands at $555.0 million.
    • INVO Bioscience (NASDAQ:INVO) stock increased by 16.36% to $1.28. The company's market cap stands at $3.1 million.

    Losers

    • NuCana (NASDAQ:NCNA) stock declined by 19.8% to $0.25 during Thursday's pre-market session. The market value of their outstanding shares is at $13.0 million.
    • Yield10 Bioscience (NASDAQ:YTEN) shares declined by 10.51% to $0.34. The company's market cap stands at $4.0 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) shares declined by 10.48% to $0.15. The market value of their outstanding shares is at $2.3 million.
    • PAVmed (NASDAQ:PAVM) stock fell 9.87% to $2.46. The market value of their outstanding shares is at $19.8 million. The company's, Q4 earnings came out 2 days ago.
    • YS Biopharma Co (NASDAQ:YS) shares decreased by 9.43% to $0.64. The market value of their outstanding shares is at $121.1 million.
    • Immuron (NASDAQ:IMRN) shares declined by 9.0% to $2.53. The company's market cap stands at $14.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $AKBA
    $AVTX
    $IMRN

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    Xilio Therapeutics Inc.
    $XLO
    8/6/2025$2.00Outperform
    Leerink Partners
    Akebia Therapeutics Inc.
    $AKBA
    6/4/2025$8.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    6/2/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    SEC Filings

    View All

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    2/27/26 9:58:50 PM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    2/27/26 3:57:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Akebia Therapeutics Inc.

    10-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    2/26/26 7:35:08 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Avalo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $25.00 from $15.00 previously

    9/17/25 11:38:46 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Gilead Sciences, Inc.

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    2/17/26 5:31:38 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Jacoby Vanessa

    3 - Sonoma Pharmaceuticals, Inc. (0001367083) (Issuer)

    2/9/26 5:00:02 PM ET
    $SNOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Accounting Officer Malabre Richard C sold $68,838 worth of shares (49,524 units at $1.39), decreasing direct ownership by 14% to 299,390 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    2/4/26 4:15:29 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    First Towers & Fiber Corp. Owns the Largest Dark Fiber Network in Central Mexico

    Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, announced today plans to further expand the leasing of its approximately 700-kilometre dark fiber optic network located in Central Mexico. The network represents the largest dark fiber infrastructure in the region, serving several of Mexico's most active industrial corridors and fastest-growing state economies.The network was constructed following the execution of a 20-year long-term dark fiber lease agreement with Telefónica, the Spanish multinationa

    2/27/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuron Reports HY26 Results and Strategic Reset

    Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler's diarrhea (Travelan®), the company is moving into high-value clinical targets like C. diff (IMM-529)Partnerships: Immuron has taken a strategic decision to pursue partnerships to fund progress of Travelan® (IMM-124E) and IMM-529 clinical programs. IMM-124E: Eligible for end o

    2/25/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 4:30:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    Financials

    Live finance-specific insights

    View All

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

    CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A

    2/19/26 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Sells Complement Inhibitor ADX-097

    -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales --  -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these

    12/1/25 7:00:00 AM ET
    $AKBA
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AKBA
    $AVTX
    $IMRN
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology